---
title: "Bioxytran 10-K: Net loss $2.12M, Loss per Share $(0.02)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282893052.md"
description: "Bioxytran reported a net loss of $2.12 million for the year ended December 31, 2025, with a loss per share of $(0.02). Operating expenses were $1.84 million, leading to a loss from operations of $(1.84 million). The company ended the period with $0.51 million in cash, insufficient to fund operations through July 2026 without additional financing. Management aims to raise $2-3 million in 2026 to sustain operations and initiate pivotal trials, while also advancing clinical candidates and achieving regulatory milestones."
datetime: "2026-04-15T20:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282893052.md)
  - [en](https://longbridge.com/en/news/282893052.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282893052.md)
---

# Bioxytran 10-K: Net loss $2.12M, Loss per Share $(0.02)

Bioxytran reported a net loss attributable to the company of $2.123077 million for the year ended December 31, 2025, with loss per common share, basic and diluted, of $(0.02) on a weighted average of 91,843,409 shares. Operating expenses totaled $1.842509 million, producing a loss from operations of $(1.842509) million. The company ended the period with $0.510 million in cash and management states existing cash is insufficient to fund operations through July 2026 without additional financing.

**Financial Highlights**

-   **Operating expenses:** $1.842509 million (Consolidated Statements of Operations)
-   **Loss from operations (Operating Income):** $(1.842509) million
-   **Net loss (Net Income) attributable to Bioxytran:** $(2.123077) million for year ended Dec 31, 2025
-   **Loss per common share, basic and diluted:** $(0.02) (weighted average common shares: 91,843,409)
-   **Cash, end of period:** $0.510 million (improved from $5,154)

**Business Highlights**

-   **Clinical development progress:** Advanced multiple candidates—BXT-25 reported positive animal toxicity results; ProLectin-M Phase 1b/2a showed faster viral clearance and a Phase 3 is planned for 3Q2026.
-   **Regulatory milestones:** FDA cleared an IND for the PROTECT trial; India’s CDSCO issued INDs for ProLectin-M, ProLectin-I and ProLectin-F, enabling clinical progression in both the U.S. and India.
-   **R&D focus:** Research and development spending increased materially in 2025 to support process, clinical and product development activities tied to advancing clinical candidates.
-   **Operational runway and funding plan:** Management is targeting $2–3 million (noting a need of approximately $3.7 million) in 2026 to sustain operations and initiate pivotal trials, with contingency plans to scale back operations if required financing is not secured.

Original SEC Filing: BIOXYTRAN, INC \[ BIXT \] - 10-K - Apr. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BIXT.US](https://longbridge.com/en/quote/BIXT.US.md)

## Related News & Research

- [Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonist](https://longbridge.com/en/news/295525258.md)
- [Bioxytran says Phase 2 trial of ProLectin-M drives SARS-CoV-2 viral load below detection by day seven](https://longbridge.com/en/news/294811633.md)
- [AXSM: 46% revenue growth in 2Q 2026 driven by AUVELITY's Alzheimer's launch and pipeline progress](https://longbridge.com/en/news/295396106.md)
- [Pfizer just raised its 2026 guidance -- but the boost leans heavily on a drug running out the patent clock](https://longbridge.com/en/news/295581210.md)
- [Egetis publishes corporate presentation on Emcitate launch, FDA review for MCT8 deficiency drug](https://longbridge.com/en/news/294971733.md)